Pharma BD Deal Intelligence
Cephalon's $2B stem-cell bet evaporated: Teva inherited it via the 2011 buyout, walked away in 2016 after funding Phase 3, and the flagship asset (Revascor) still isn't FDA-approved 15 years later.
Full analysis, sources & comparables →Cephalon and Mesoblast enter into strategic alliance; in exchange for exclusive worldwide rights, Cephalon will make an upfront payment totaling US$130 million…
GEN noted Cephalon's $350M immediate commitment ($130M upfront + $220M equity) signaled 'genuine confidence rather than transactional collaboration' and gave…
Teva (which inherited the rights via its Cephalon acquisition) returned the experimental stem cell heart therapy to Mesoblast, exiting the program; Mesoblast…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Cephalon and Mesoblast strategic alliance: $130M upfront + up to $1.7B regulatory milestones for exclusive worldwide rights to MPC therapeutics in CV/CNS. Cephalon also took 19.99% equity stake. Largest licensing deal of 2010.
Cephalon's $2B stem-cell bet evaporated: Teva inherited it via the 2011 buyout, walked away in 2016 after funding Phase 3, and the flagship asset (Revascor) still isn't FDA-approved 15 years later.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cephalon Inc. / Mesoblast Limited (this deal) | 2010 | $2.0B | 19 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
| Cephalon Inc. / Cell Therapeutics, Inc. | 2005 | $70M | 74 |
| Cephalon Inc. / Anesta Corp. | 2001 | $444M | 65 |
| Cephalon Inc. / Anesta Corp. | 2000 | $444M | 64 |
← Browse all deals · How we score deals
More: 2010 deals · Cephalon Inc. deals · Neurology deals